Clinical Trials
Alfred Health Expands Oracle EHR to Enhance Cancer Care and Clinical Trial Access
Leading Victorian healthcare network, Alfred Health, has extended its long-standing Oracle Health footprint with Oracle's Oncology electroni...
August 14, 2024 | News
Mabwell's Nectin-4 Targeting ADC Receives Breakthrough Therapy Designation in China for Urothelial Carcinoma
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821)...
August 13, 2024 | News
Lynk Pharmaceuticals Reports Positive Phase 1b Results for Skin-Restricted JAK Inhibitor LNK01004 in Atopic Dermatitis Treatment
Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, announced positiv...
August 13, 2024 | News
Biosyngen’s EBV-Specific CAR-T Therapy, BRG01, Secures FDA Approval for Pivotal Phase II Trial in U.S.
Biosyngen is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with...
August 13, 2024 | News
Angiex Initiates Patient Dosing in Phase 1 Clinical Trial of AGX101, a First-in-Class TM4SF1-Directed Antibody-Drug Conjugate for Solid Cancers
Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that patient dosing has begun for t...
August 12, 2024 | News
Pulnovo Medical Launches Asia's First International Clinical Study on PADN at Singapore's National Heart Centre
Pulnovo Medical Limited,a globally recognized device pioneer in the treatment of Pulmonary Hypertension (PH) and Heart Failure (HF), is pleased to announce...
August 10, 2024 | News
NEC Bio Therapeutics and AGC Biologics Partner to Enhance Production of Personalized Cancer Vaccine
NEC Bio Therapeutics and AGC Biologics have announced a partnership to advance the production of NECVAX-NEO1, an orally delivered, bacteria-based D...
August 08, 2024 | News
Senhwa Biosciences Receives FDA Green Light for Phase I/II Trial of Silmitasertib in Pediatric Relapsed Refractory Solid Tumors
Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious disea...
August 07, 2024 | News
Oxford Nanopore Partners with Singapore's NPM to Map Genomic Diversity of Major Ethnic Groups
Oxford Nanopore Technologies (Oxford Nanopore) has announced a landmark project with Singapore's National Precision Medicine (NPM) programme, led by Precis...
August 05, 2024 | News
Bayer Submits New Drug Application to FDA for Elinzanetant, a Novel Non-Hormonal Treatment for Menopausal Hot Flashes
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency...
August 02, 2024 | News
Bridge Biotherapeutics Completes Patient Enrollment for Phase 2 Study of BBT-877 in IPF Treatment
Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in South Korea developing novel drugs for fibrosis and cancer, an...
July 30, 2024 | News
Menarini Group Announces Positive Phase 3 Trial Results for Obicetrapib in Lowering LDL-C
-- Achieved primary endpoint of LS mean reduction in LDL-C on top of maximally tolerated lipid modifying therapies at week 12 with statistically ...
July 30, 2024 | News
Daewoong Pharmaceutical's Bersiporocin Shows Positive Safety Data in Phase 2 Trial for IPF
Daewoong Pharmaceutical (Co-CEOs Chang-Jae Lee and Seongsoo Park) announced a significant milestone in the development of 'Bersiporocin (DWN...
July 30, 2024 | News
Eluminex Biosciences Administers First Dose of EB-105 to Diabetic Macular Edema Patient in US
Eluminex Biosciences announced that their tri-specific fusion antibody drug, EB-105, has administered its first dose to a diabetic macular edema patient in...
July 29, 2024 | News
Most Read
- How Does GLP-1 Work?
- Innovations In Magnetic Resonance Imaging Introduced By United Imaging
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
Editor Picks
